Pretrial proceedings for testosterone drug therapy lawsuit claims are moving forward while the number of low testosterone side-effects lawsuit filings continued at a steady rate. A recent review of court documents indicates that over 2,700 testosterone complaints are currently pending in the U.S. District Court, Northern District of Illinois, as of October 15th.
Testosterone treatment complaints allege that men who've used testosterone therapy suffer heart attacks, strokes, blood clots, and cardiac death as a result of prescription testosterones including AndroGel, Axiron and Androderm.
Testosterone gels, patches, creams, and injections have been approved by the U.S. Food and Drug Administration (FDA) to treat hypogonadism, a condition in which men suffer from low testosterone due to a medical condition, not necessarily the aging process.
Aside from pharmaceutical giants AbbVie and Abbott Laboratories, there are several other testosterone makers that are named as defendants in the MDL. They include:
- Actavis, Inc. and Watson Pharmaceuticals, the makers of AndroDerm.
- Auxilium Pharmaceuticals, Inc., makers of Testin
- Endo Pharmaceuticals, Inc., which makes Delatestryl and Fortesta
- Eli Lilly and Company and Lilly USA LLC, the makers of Axiron
- Pfizer, Inc. and its subsidiary Pharmacia & Upjohn CO. the makers of Depo-Testosterone
There is growing concern amongst law officials and medical researchers that the increasing number of testosterone therapy lawsuit filings is indicative of an increase in risk of cardiac events as a result of the treatment.
Lowe Law Group is currently representing men from across the country in testosterone treatment lawsuits and continues to offer legal evaluation to men, or their survivors, who believe they have experienced cardiac events due to testosterone therapy drugs.
Testosterone products have been under investigation by the FDA since January of 2014. The federal regulatory agency announced that it was re-evaluating the safety and effectiveness of prescription testosterone medication due to complaints of cardiovascular risks associated with the products.
The review included a JAMA study published in November 2013 which indicated that testosterone replacement therapy appeared to raise the risk of death, heart attack, and stroke in men by as much as 30 per cent.